Zacks CommentaryOCT 213 min read$HSCS

HeartSciences Inc. (HSCS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for HeartSciences Inc. (HSCS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Original reporting

Zacks Commentary · Zacks Equity Research

Published Oct 21, 2025, 1:55 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Oct 22, 2025, 1:01 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

HeartSciences Inc. (HSCS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — source image — Source · www.zacks.com

Decision brief

The 30-second read

$HSCSBullishMed

Why it matters

The formation of a hammer chart pattern suggests support at current levels, which could lead to a reversal if confirmed by volume and subsequent price action.

Market read

The news is directly relevant to HSCS and may influence short-term trading decisions, especially among technical traders.

What to watch

Potential upcoming negative news, sector-wide downturns, or macroeconomic factors could negate the technical signals and lead to further declines.

Timing: Immediate, as the news is recent and indicates a potential short-term reversal.

Background

HeartSciences Inc. has recently experienced a decline, but technical analysis indicates a potential bottom formation.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HSCSBullishMedium confidence

Context

The news pertains directly to HeartSciences Inc. (HSCS), highlighting technical support and earnings estimate revisions.

Expected impact

Moderate upward movement in the near term, with potential for a short-term rally.

Evidence & confidence

Technical pattern and earnings revisions support a bullish outlook, but limited fundamental data and market conditions introduce some uncertainty.

Market effects

Sector

Potential positive impact on the biotech and medical device sectors, as HSCS operates within this space.

Regional

Limited regional impact; primarily relevant to US markets where HSCS is listed.

Global

Low, as the news is specific to a single company and sector.

Counterpoint

What could challenge this read

The technical support may be a false signal, and the stock could continue to decline if broader market conditions worsen or if earnings revisions do not materialize as expected.

Key entities

Company
HeartSciences Inc.
A medical device company specializing in cardiac monitoring solutions.

Read at source ← All news

AUG 21

$ELOXHighAI 8/10

Top Biotech Gainers: ELOX Clinical Progress, VOGX IPO Success, ARCT Pipeline Updates Drive Gains

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

rttnews.com3 min

JUL 29

$HSCSMed

HeartSciences Inc. (HSCS): Results of Operations and Financial Condition

HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029962701ex99-1.htm PRESS RELEASE, DATED JULY 29, 2026 Exhibit 99.1 HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results ● Company believes proposed

SEC EDGAR 8-K6 min

JUN 25

$HSCSMedAI 8/10

Zcash Miner Fortitude Merging with HeartSciences to Go Public

Fortitude Mining Holdings, a Zcash miner, agreed to merge with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock deal to take the combined company public. The firm is expected to trade on Nasdaq as “TUDE” under the Fortitude brand, with closing expected in 2H 2026. Fortitude reported ~$90M fiscal 2025 gross revenue and ~$20M adjusted EBITDA, and said 48 MW owned power could rise to ~80 MW by end-2026.

finance.yahoo.com3 min

JUN 23

$HSCSMed

Fortitude And HeartSciences Announce Merger To Form Public Zcash Mining Platform; Stock Up

Fortitude Mining Holdings and HeartSciences agreed to merge in an all-stock deal to create a public Zcash mining platform. The combined company is expected to trade under ticker TUDE pending approval, with a target close in H2 2026. Fortitude CEO Andrea Childs will lead the combined team; HeartSciences CEO Andrew Simpson will run the healthcare unit. Fortitude reported annualized 157,000 ZEC production as of May 31, 2026.

rttnews.com4 min

AUG 24

$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.

yahoo.com2 min

AUG 23

$CRWDMed

Analysts Back CrowdStrike, Dell and SanDisk Growth

Wall Street analysts maintain positive outlooks on CrowdStrike, Dell, and SanDisk, citing long-term growth in cybersecurity, AI infrastructure, and storage. CrowdStrike's price target raised to $245 by Truist, Dell's to $550 by Evercore, and SanDisk's to $2,250 by J.P. Morgan, all with buy ratings.

ozarab.media2 min